Capula Management LTD Eli Lilly & CO Call Options Transaction History

Capula Management LTD

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$772.14 - $960.02 $463,284 - $576,012	-600 Reduced 42.86%	800 $708,000
Q2 2024 Aug 05, 2024	BUY	$724.87 - $909.04 $1.01 Million - $1.27 Million	1,400 New	1,400 $1.27 Million
Q3 2023 Nov 03, 2023	BUY	$434.7 - $599.3 $999,810 - $1.38 Million	2,300 New	2,300 $1.24 Million
Q1 2023 May 10, 2023	BUY	$310.63 - $364.82 $16.4 Million - $19.3 Million	52,900 Added 440.83%	64,900 $22.3 Million
Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $10.1 Million - $11.8 Million	-31,400 Reduced 72.35%	12,000 $4.39 Million
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $12.9 Million - $14.7 Million	43,400 New	43,400 $14 Million
Q4 2019 Feb 14, 2020	BUY	$106.92 - $132.43 $2.32 Million - $2.87 Million	21,700 New	21,700 $2.85 Million

4,003

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $713B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Capula Management LTD, based on Form 13F filings with the SEC.

Stay updated on Capula Management LTD with notifications on news.